Cardiac amyloidosis – Basic Information

Go back

Cardiac amyloidosis is a progressive condition where misshapen proteins build up in the heart muscle, making it thick and stiff, ultimately disrupting the heart’s ability to pump blood effectively throughout the body.

When someone develops cardiac amyloidosis, abnormal proteins called amyloid begin depositing in the spaces between heart muscle cells. These deposits are not supposed to be there, and over time they accumulate and change the heart’s structure. The heart walls become thicker and lose their flexibility, which makes it increasingly difficult for the heart to do its job of pumping blood. The condition gradually worsens, and if left untreated, it can lead to serious complications including heart failure and dangerous heart rhythm problems.

This condition is a leading cause of restrictive cardiomyopathy, which is a type of heart muscle disease where the heart becomes stiff and cannot relax properly between beats. Although cardiac amyloidosis was once considered rare and essentially untreatable, medical advances in recent years have dramatically changed the outlook for people diagnosed with this disease. Better diagnostic tools now allow doctors to identify it earlier, and new treatments can slow its progression and manage symptoms more effectively.

How Common Is Cardiac Amyloidosis

Cardiac amyloidosis is more common than previously thought, largely because it has historically been underdiagnosed. The disease often goes unrecognized because its symptoms can resemble other, more familiar heart conditions. Light chain amyloidosis, one of the main types that affects the heart, occurs in more than 10 individuals per million people each year. The actual number of people living with cardiac amyloidosis may be much higher, as many cases remain undetected until advanced stages.

Certain groups of people face higher risks of developing this condition. Advanced age is a significant risk factor, and the disease is particularly common among older adults. Men are more likely to develop cardiac amyloidosis than women. People of African and Caribbean descent also have elevated risk for certain types of the disease. The condition can run in families in some cases, especially with hereditary forms of transthyretin amyloidosis, where genetic mutations are passed down through generations.

The disease is emerging as an important cause of heart failure and heart rhythm problems, especially in the elderly population. As awareness among healthcare providers increases and diagnostic methods improve, more cases are being identified. This heightened recognition is crucial because early detection leads to earlier treatment, which can significantly improve outcomes and quality of life for those affected.

What Causes This Heart Condition

The root cause of cardiac amyloidosis depends on which type of the disease a person has. The condition results from what doctors call “protein misfolding,” where normally soluble proteins in the bloodstream become insoluble and deposit abnormally in tissues and organs. In the case of cardiac amyloidosis, these misfolded proteins accumulate specifically in the heart, though they may also deposit in other organs like the kidneys, intestinal tract, nerves, and ligaments.

There are two main types of amyloidosis that commonly affect the heart. The first is light-chain amyloidosis, abbreviated as AL, where the “A” stands for amyloid and “L” stands for light chain type. This form involves abnormal production of immunoglobulin light chains, which are proteins normally made by the bone marrow to fight infection. In AL amyloidosis, plasma cells in the bone marrow produce abnormal light chains that clump together and form amyloid deposits. Bone marrow disorders are the underlying cause of this type.

The second major type is transthyretin amyloidosis, known as ATTR. This condition involves a protein called transthyretin, which normally transports thyroid hormone and vitamin A through the bloodstream. The protein is produced in the liver, but for various reasons it can become unstable and misfold. There are two subtypes of ATTR: hereditary (also called variant) ATTR, caused by genetic mutations in the transthyretin gene that are passed down in families, and wild-type ATTR, which occurs due to aging-related changes in the protein without any genetic mutation. Wild-type ATTR is often a disease of older adults and happens when the transthyretin protein becomes unstable simply with age.

⚠️ Important
If you have cardiac amyloidosis, there is a good chance you also have amyloid buildup in other areas of your body. While the heart deposits tend to cause the most severe health problems, amyloid can affect kidneys, nerves, the digestive system, and other organs. This is why cardiac amyloidosis is considered part of a systemic disease that affects multiple body systems.

Who Is at Higher Risk

Several factors increase the likelihood of developing cardiac amyloidosis. Age plays a significant role, as the risk increases substantially in older adults. This is particularly true for wild-type ATTR amyloidosis, which typically appears in people over 60 and becomes more common with advancing age. The hereditary form of ATTR can appear earlier in life, depending on the specific genetic mutation involved.

Gender matters when it comes to risk. Men are more likely to develop cardiac amyloidosis than women. This difference is especially pronounced with wild-type ATTR amyloidosis, which predominantly affects older men. The reasons for this gender difference are not fully understood, but it is a consistent pattern observed across populations.

Race and ethnicity influence risk as well. People of African descent and those from the Caribbean face higher risk for certain forms of the disease. Specific genetic mutations that cause hereditary ATTR amyloidosis are more common in these populations, though the condition can affect people of any racial or ethnic background.

For AL amyloidosis specifically, having a plasma cell disorder or other bone marrow condition increases risk. These underlying blood disorders can lead to the abnormal production of light chain proteins that eventually form amyloid deposits. People with chronic or infectious diseases may also face elevated risk for developing amyloidosis.

Family history is crucial, particularly for hereditary ATTR amyloidosis. If someone in your family has been diagnosed with this form of cardiac amyloidosis, other family members should be screened. Early diagnosis in family members allows for monitoring and earlier initiation of treatment, which can help reduce the damage to the heart and other organs. Genetic testing can identify whether someone carries the mutations that cause hereditary ATTR, even before symptoms appear.

Recognizing the Symptoms

Cardiac amyloidosis is a progressive condition that typically gets worse over time. In the early stages, symptoms may be subtle or even absent, which is one reason the disease often goes undiagnosed for extended periods. As the condition advances, people begin experiencing symptoms similar to heart failure, and these symptoms become more severe as more amyloid deposits accumulate in the heart.

Shortness of breath is one of the most common symptoms. At first, people may notice they get winded more easily when exercising or climbing stairs. As the disease progresses, breathing difficulties can occur even during normal daily activities like walking across a room. In more severe cases, shortness of breath happens even at rest or when lying down, making it difficult to sleep flat and requiring extra pillows to prop up in bed.

Swelling is another hallmark symptom. Fluid tends to accumulate in the lower parts of the body due to gravity, so people often notice their legs and ankles becoming puffy and retaining fluid. The abdomen can also swell as fluid builds up there. This swelling is usually worse at the end of the day and may improve somewhat after a night of sleep with legs elevated.

Fatigue affects many people with cardiac amyloidosis. This is not just ordinary tiredness that goes away after rest, but a deep, persistent exhaustion that lasts for days. The fatigue results from the heart’s reduced ability to pump blood efficiently, meaning less oxygen reaches muscles and organs throughout the body. People may find they lack energy for activities they used to do easily.

Heart rhythm disturbances are common with this condition. Many people experience palpitations, which feel like the heart is racing, pounding, fluttering, or skipping beats. These sensations may occur during normal daily routines when they shouldn’t be happening. Some people develop atrial fibrillation, an irregular heart rhythm that can increase the risk of stroke and other complications.

Because amyloid often deposits in organs and tissues beyond the heart, people may experience additional symptoms throughout the body. Peripheral neuropathy, which causes tingling, numbness, or pain in the hands and feet, is common. Some people develop dysautonomia, where the autonomic nervous system is affected, leading to lightheadedness, dizziness, or sudden drops in blood pressure when standing up or changing position. Digestive symptoms like diarrhea, nausea, poor appetite, or unexplained weight loss may occur if amyloid affects the gastrointestinal tract. Other possible symptoms include easy bruising, purple spots around the eyelids, an enlarged tongue, unexplained back pain, or pain and numbness in the arms or hands from carpal tunnel syndrome.

Ways to Prevent or Reduce Risk

For most types of cardiac amyloidosis, there are no specific prevention strategies because the underlying causes involve either genetic factors or age-related changes that cannot be avoided. However, there are important steps that can reduce the impact of the disease and improve outcomes, especially when the condition runs in families.

If you have hereditary ATTR amyloidosis in your family, the most important preventive step is screening. Family members of someone diagnosed with hereditary ATTR should undergo genetic testing to determine whether they carry the mutation. Early identification allows for close monitoring even before symptoms develop. If the disease is detected early through regular heart evaluations, treatment can begin sooner, potentially slowing disease progression and lessening the damage to the heart and other organs.

For people already diagnosed with cardiac amyloidosis, making heart-healthy lifestyle choices can help manage symptoms and support overall cardiovascular health. While these changes do not reverse amyloid deposits, they can improve quality of life and help the heart function as well as possible given the circumstances. This includes eating a balanced, nutritious diet, staying as physically active as your symptoms allow under medical supervision, managing stress, and getting quality sleep.

Working closely with your healthcare team is essential for optimal management. Regular monitoring allows doctors to track disease progression and adjust treatments as needed. Because cardiac amyloidosis can affect multiple body systems, coordination among different specialists is often necessary. Alerting your care team to any new symptoms, whether they involve the heart or other organs, ensures that all aspects of the disease are addressed.

How the Disease Changes Heart Function

Understanding what happens inside the heart when amyloid deposits helps explain why symptoms develop and why treatment is so important. Cardiac amyloidosis is an infiltrative disease, meaning that foreign material infiltrates and accumulates where it does not belong. In this case, amyloid fibrils made of misfolded proteins deposit in the extracellular spaces between heart muscle cells. These deposits are insoluble, meaning they do not dissolve, and they gradually accumulate over time.

As amyloid builds up in the heart tissue, it causes the heart walls to thicken. This thickening is particularly noticeable in the left ventricle, which is the heart’s main pumping chamber. The amyloid infiltration reduces the heart’s compliance, which is its ability to relax and expand. A normal heart muscle is flexible and elastic, allowing it to fill with blood easily during the relaxation phase between beats. When amyloid makes the heart stiff, it cannot relax properly or fill with enough blood.

This stiffness leads to diastolic dysfunction, where the heart has trouble filling with blood during the diastolic phase. Because less blood enters the heart, less blood gets pumped out to the body with each heartbeat. The heart tries to compensate by beating faster or with more force, but these efforts strain the already compromised heart muscle. Over time, this leads to heart failure with preserved ejection fraction, where the heart’s squeezing ability may initially remain relatively normal but the filling problem causes all the symptoms of heart failure.

The amyloid deposits do not just affect the heart muscle itself. They can infiltrate the heart’s electrical conduction system, disrupting the normal electrical signals that coordinate heartbeats. This interference can cause conduction system disease, where electrical signals move too slowly through the heart. It can also trigger various arrhythmias, including atrial fibrillation, slow heart rates called bradycardia, or fast abnormal rhythms from the ventricles called ventricular tachycardia. These rhythm problems can be dangerous and sometimes require treatment with medications or devices like pacemakers.

The changes to heart structure and function also affect blood flow. Reduced cardiac output means that organs throughout the body receive less oxygen and nutrients. The kidneys, which depend on adequate blood flow to filter waste from the blood, can become impaired, sometimes leading to cardiorenal syndrome where heart and kidney problems worsen each other. Fluid backs up in the circulatory system because the heart cannot pump it forward effectively, causing the swelling seen in the legs, abdomen, and sometimes lungs.

⚠️ Important
Cardiac amyloidosis can lead to serious complications beyond heart failure. The condition increases risk of stroke, partly due to atrial fibrillation and blood clots that can form in the stiff heart chambers. Bundle branch block, where electrical signals are delayed traveling through the heart, is another complication. Early recognition and treatment of cardiac amyloidosis are essential to reduce these risks and improve outcomes.

Ongoing Clinical Trials on Cardiac amyloidosis

  • Study to Diagnose Cardiac Amyloidosis in Patients with Monoclonal Component Using Florbetaben (18F) PET-CT

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Long-Term Safety Study of NTLA-2001 for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy or Transthyretin Amyloidosis-Related Cardiomyopathy

    Recruiting

    1 1 1
    Investigated drugs:
    France Sweden
  • Study on the Effects of Dobutamine on Heart Function in Patients with Wild-type Transthyretin Amyloid Cardiomyopathy

    Recruiting

    1 1 1
    Investigated diseases:
    Denmark
  • Study on the Impact of Dapagliflozin on Quality of Life and Exercise Capacity in Patients with Transthyretin Cardiac Amyloidosis

    Recruiting

    1 1 1
    Investigated drugs:
    Italy
  • Study to Evaluate the Safety and Effectiveness of Vutrisiran in Patients with Transthyretin Amyloidosis and Heart Disease

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Italy +5
  • Study on the Use of Flutemetamol (18F) for Diagnosing Cardiac Amyloidosis in Patients

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy
  • Study of Patisiran for Patients with Transthyretin Amyloidosis and Heart Disease

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Czechia Denmark France Italy The Netherlands +2
  • Study of Vutrisiran for Patients with Transthyretin Amyloidosis and Heart Disease

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Croatia Czechia Denmark France +10
  • Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +8
  • Study on the Effectiveness and Safety of CAEL-101 with Drug Combination for Patients with Advanced AL Amyloidosis

    Not recruiting

    1 1 1
    Investigated diseases:
    Austria Belgium Czechia France Germany Greece +3

References

https://my.clevelandclinic.org/health/diseases/22598-cardiac-amyloidosis

https://www.ncbi.nlm.nih.gov/books/NBK580521/

https://www.mayoclinic.org/tests-procedures/heart-transplant/multimedia/how-does-amyloid-affect-the-heart/vid-20207025

https://www.massgeneralbrigham.org/en/patient-care/services-and-specialties/heart/conditions/cardiac-amyloidosis

https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-19/cardiac-amyloidosis-epidemiology-diagnosis-and-therapy

http://www.cardiosmart.org/topics/cardiac-amyloidosis

https://www.mayoclinic.org/tests-procedures/heart-transplant/multimedia/cardiac-amyloidosis-treatment-options/vid-20207033

https://pmc.ncbi.nlm.nih.gov/articles/PMC8932359/

https://my.clevelandclinic.org/health/diseases/22598-cardiac-amyloidosis

https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-19/cardiac-amyloidosis-epidemiology-diagnosis-and-therapy

https://www.ummhealth.org/services-treatments/heart-and-vascular-care/cardiology/cardiac-amyloidosis-program

https://www.adventhealth.com/medical/adventhealthmd/blog/new-treatments-cardiac-amyloidosis-emerging-timely-diagnosis-remains-essential-improving-outcomes

https://www.acc.org/Latest-in-Cardiology/Articles/2024/04/01/00/42/Feature-Cardiac-Amyloidosis-and-How-to-Stop-Missing-the-Diagnosis

http://www.cardiosmart.org/topics/cardiac-amyloidosis/living-with-cardiac-amyloidosis

https://www.everydayhealth.com/amyloidosis/self-care-tips-for-transthyretin-amyloid-cardiomyopathy/

https://my.clevelandclinic.org/health/diseases/22598-cardiac-amyloidosis

https://arci.org/resource/amyloidosis-and-nutrition/

https://www.nghs.com/2023/02/13/can-you-live-a-normal-life-with-cardiac-amyloidosis

https://www.templehealth.org/about/blog/cardiac-amyloidosis-5-things-know-about-stiff-heart-syndrome

https://www.mpeurope.org/what-we-do/educational-resources/qas/living-with-al-amyloidosis/

FAQ

Can you live a normal life with cardiac amyloidosis?

While cardiac amyloidosis is a serious condition that progresses over time, many people can maintain quality of life with proper treatment and management. The outlook depends on the type of amyloidosis, how early it is diagnosed, and how well treatments work. ATTR amyloidosis, which represents most cases, is generally less severe and more treatable than AL amyloidosis. Recent medical advances have dramatically improved outcomes, with new therapies that can slow disease progression and manage symptoms effectively. However, adjustments to daily life may be necessary as symptoms develop.

How do doctors diagnose cardiac amyloidosis?

Diagnosis involves multiple tests because cardiac amyloidosis is part of a systemic disease affecting the whole body. Doctors use blood and urine tests to check for amyloid proteins and heart function markers, an electrocardiogram to assess the heart’s electrical activity, and imaging tests like echocardiogram, cardiac MRI, and nuclear imaging scans to look for thickened heart muscle and amyloid buildup. In some cases, a biopsy of heart tissue or other organs is needed to confirm amyloid presence. Genetic testing helps determine if hereditary forms are involved. The key is that providers must first suspect the condition based on symptoms and red flags, which is why heightened awareness among doctors is crucial.

What is the difference between AL and ATTR amyloidosis?

AL (light-chain) amyloidosis occurs when abnormal proteins from bone marrow plasma cells create amyloid deposits. It tends to progress more rapidly and is generally more severe. ATTR (transthyretin) amyloidosis involves proteins produced by the liver that become unstable and misfold. ATTR has two subtypes: hereditary (caused by genetic mutations passed down in families) and wild-type (caused by aging-related changes, typically appearing in older adults). Treatment approaches differ significantly between the two types, with AL requiring chemotherapy and immunotherapy to target plasma cells, while ATTR uses medications to stabilize the protein or prevent the liver from making it.

Should my family members be tested if I have cardiac amyloidosis?

If you have hereditary ATTR amyloidosis, yes, your family members should be screened. This type is caused by genetic mutations that can be passed down through generations. Genetic testing can identify whether family members carry the mutation even before symptoms appear. Early detection allows for monitoring and earlier treatment initiation, which can help reduce organ damage. For AL amyloidosis and wild-type ATTR, family screening is not typically necessary because these forms are not inherited. Your doctor can help determine which type you have and whether family screening is appropriate.

Why is cardiac amyloidosis often missed or diagnosed late?

Cardiac amyloidosis is frequently underdiagnosed for several reasons. In early stages, symptoms may be subtle or completely absent. When symptoms do appear, they often mimic more common conditions like typical heart failure, making doctors less likely to consider the rarer diagnosis of cardiac amyloidosis. The disease was historically considered extremely rare with no treatment options, so many providers were not trained to recognize it. However, awareness is now increasing among healthcare professionals, and with improved diagnostic tools and new effective treatments available, earlier detection is becoming more common. The key is clinical suspicion—doctors must think to look for it.

🎯 Key takeaways

  • Cardiac amyloidosis occurs when misfolded proteins deposit in the heart, making it thick and stiff, ultimately leading to heart failure and rhythm problems.
  • The two main types affecting the heart are AL amyloidosis (from bone marrow) and ATTR amyloidosis (from the liver), with ATTR being more common and generally more treatable.
  • The disease is more common than previously thought but frequently goes undiagnosed because early symptoms are subtle and resemble more common heart conditions.
  • Older adults, men, and people of African or Caribbean descent face higher risk, while hereditary forms can run in families requiring screening of relatives.
  • Common symptoms include shortness of breath, swelling in legs and abdomen, persistent fatigue, and heart palpitations, along with possible numbness in hands and feet.
  • Recent medical advances have dramatically improved the outlook for cardiac amyloidosis, with new treatments that can slow disease progression and new diagnostic tools enabling earlier detection.
  • Diagnosis requires multiple tests including blood work, imaging studies like echocardiogram and cardiac MRI, and sometimes tissue biopsy to confirm amyloid presence and determine type.
  • Early recognition and treatment are essential for better outcomes, making it crucial for both patients and doctors to be aware of the red flags pointing to this condition.